Context Therapeutics (NASDAQ:CNTX) Announces Quarterly Earnings Results

Context Therapeutics (NASDAQ:CNTX) issued its quarterly earnings data on Thursday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01, reports.

Context Therapeutics Trading Up 0.2 %

Shares of CNTX stock traded up $0.00 on Friday, hitting $0.77. 60,567 shares of the stock were exchanged, compared to its average volume of 388,777. The firm has a market capitalization of $57.88 million, a P/E ratio of -0.85 and a beta of 2.06. The business has a 50-day moving average of $0.85 and a 200 day moving average of $1.44. Context Therapeutics has a fifty-two week low of $0.64 and a fifty-two week high of $2.75.

Analysts Set New Price Targets

Several research firms have recently commented on CNTX. JMP Securities began coverage on Context Therapeutics in a research note on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 target price for the company. D. Boral Capital reissued a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research note on Friday. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Context Therapeutics in a research note on Friday. Finally, Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $6.17.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.